- Home
- / Shandong Saito Biotechnology
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Shandong Saito Biotechnology financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
¥25.6
2024-10-29
Market Capitalization
¥5.1 B
2024-10-29
Revenue
¥904.3 M
FY, 2024
CreditSafe Score
?
Score changed on Jun 11, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| CNY | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 |
|---|---|---|---|---|---|---|---|
| Revenue | 892.6M | 859.6M | 799.2M | 1.2B | 1.2B | 1.2B | 904.3M |
| Cost of goods sold | 784.8M | 730.1M | 805.6M | 937.0M | 1.0B | 994.2M | 784.9M |
| Gross profit | 260.6M | 230.0M | 99.9M | 257.5M | 260.7M | 271.8M | 171.7M |
| Gross profit margin, % | 12.5% | 22.4% | 19.0% | ||||
| Operating expense total | 49.9M | (52.0M) | 42.3M | 47.1M | 24.1M | 32.6M | 30.2M |
| Depreciation and amortization | 67.7M | 201.7M | 172.7M | 133.4M | 160.8M | 170.6M | 170.0M |
| EBITDA | 212.0M | 283.9M | 57.6M | 214.2M | 240.7M | 243.4M | 147.7M |
| EBITDA margin, % | 7.2% | 20.1% | 16.3% | ||||
| EBIT | 147.5M | 83.9M | (166.9M) | 79.9M | 75.0M | 87.1M | (82.9M) |
| EBIT margin, % | -20.9% | 7.2% | -9.2% | ||||
| Interest income | 1.1M | 1.3M | 1.6M | 2.7M | 3.7M | 4.7M | 2.4M |
| Interest expense | 15.3M | 31.1M | 34.0M | 30.2M | 36.9M | 37.7M | 30.9M |
| Pre tax profit | 149.5M | 64.7M | (192.4M) | 54.3M | 47.9M | 53.5M | (102.7M) |
| Income tax expense | 22.6M | 15.7M | (2.8M) | 18.5M | 5.4M | 4.9M | (1.4M) |
| Net Income | 126.9M | 49.0M | (189.6M) | 35.8M | 42.5M | 48.5M | (101.3M) |